A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Sarilumab (Primary) ; Simvastatin
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Sanofi
- 08 Oct 2016 Results published in the Clinical Pharmacokinetics
- 06 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record
- 07 Oct 2014 Planned End Date changed from 1 Oct 2015 to 1 Mar 2016 as reported by ClinicalTrial.gov record.